Lv7
4010 积分 2021-11-10 加入
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
15小时前
已完结
Differential impact of immune-mediated inflammatory diseases before versus after cancer on patient survival: a nationwide cohort study
1个月前
已完结
Timing matters in diagnosis of cancer with immune-mediated inflammatory disease
1个月前
已完结
CONSORT 2025 Statement
4个月前
已完结
CONSORT 2025 statement: updated guideline for reporting randomised trials
4个月前
已完结
Depression — Understanding, Identifying, and Diagnosing
1年前
已关闭
Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial
1年前
已完结
The 47,XYY syndrome, 50 years of certainties and doubts: A systematic review
1年前
已完结
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
1年前
已完结
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
1年前
已完结
皖公网安备34019202002308
